Literature DB >> 8156094

Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.

J O Jørgensen1, L Thuesen, J Müller, P Ovesen, N E Skakkebaek, J S Christiansen.   

Abstract

Growth hormone (GH) replacement therapy in several controlled short-term trials have shown unanimous beneficial effects on body composition and other features. To evaluate more long-term effects we report data from 3 years of uninterrupted GH therapy in 10 GH-deficient adults who had all completed a previous double-blind placebo-controlled study and who also had been studied after 16 months of open GH therapy. No further increase in linear height was observed. The initial increase in thigh muscle volume was maintained after 3 years of GH therapy. A slight increase in body weight and thigh fat volume was recorded. Exercise capacity and isometric muscle strength were increased significantly compared to the initial placebo period. This was associated with stabilized levels of resting heart rate and blood pressure. Glycosylated hemoglobin levels were normal and did not change during the study. A standard oral glucose tolerance test performed at the end of the study revealed no evidence of glucose intolerance. No side-effects were reported. Compared to an age- and sex-matched group of healthy untreated subjects, thigh muscle volume, exercise capacity and isometric muscle strength had become normalized from subnormal levels after 3 years of GH therapy. We conclude that long-term GH replacement therapy in GH-deficient adults is associated with preserved beneficial effects on body composition and physical performance, resulting in a near normalization of several previously abnormal features and adding new merits to this treatment modality.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8156094     DOI: 10.1530/eje.0.1300224

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  18 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

4.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement.

Authors:  Luciana Diniz Carneiro Spina; Débora Vieira Soares; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Flávia Lúcia Conceição; Mário Vaisman
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 6.  Optimal management of sarcopenia.

Authors:  Louise A Burton; Deepa Sumukadas
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

7.  Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry.

Authors:  Pamela U Freda; Wei Shen; Carlos M Reyes-Vidal; Eliza B Geer; Fernando Arias-Mendoza; Dympna Gallagher; Steven B Heymsfield
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

Review 8.  Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

Authors:  Silvia Giovannini; Emanuele Marzetti; Stephen E Borst; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2008-08-13       Impact factor: 5.432

9.  The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat.

Authors:  Melissa Westwood; Arfa R Maqsood; Mattea Solomon; Andrew J Whatmore; Julian R E Davis; Robert C Baxter; Evelien F Gevers; Iain C A F Robinson; Peter E Clayton
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

Review 10.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.